Related Experiment Videos
Drug-induced pulmonary disease: an update
1Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia 19104.
Journal of Thoracic Imaging
|January 1, 1991
Summary
This review updates knowledge on drug-induced pulmonary disorders, highlighting recent findings on newer agents like cyclosporine and amiodarone. It also covers common drugs causing lung toxicity.
Area of Science:
- Pulmonary Medicine
- Pharmacology
- Toxicology
Background:
- Drug-induced lung injury is a significant clinical concern.
- Recent research has focused on newer therapeutic agents and their pulmonary effects.
- Understanding these toxicities is crucial for patient safety.
Purpose of the Study:
- To provide an updated review of drug-induced pulmonary disorders.
- To focus on newer pharmaceutical agents with recently studied lung effects.
- To include a review of common cytotoxic and noncytotoxic agents causing pulmonary toxicity.
Main Methods:
- Literature review of recent studies on drug-induced lung injury.
- Focus on specific newer agents: cyclosporine, cytosine arabinoside (Ara-C), amiodarone, interleukin-2 (IL-2), OKT3, tricyclic antidepressants, and bromocriptine.
- Inclusion of a summary of established pulmonary toxicants.
Main Results:
- Newer agents like cyclosporine, Ara-C, amiodarone, IL-2, OKT3, tricyclic antidepressants, and bromocriptine have demonstrated pulmonary toxicity.
- Established cytotoxic and noncytotoxic drugs continue to be significant causes of lung injury.
- The spectrum of drug-induced lung disease is broad and evolving.
Conclusions:
- Clinicians should be aware of the potential for pulmonary toxicity from both novel and established medications.
- Early recognition and management are key to improving outcomes in drug-induced lung injury.
- Continued research is needed to further elucidate mechanisms and develop targeted therapies.